Notice for elexacaftor, tezacaftor and ivacaftor (Vertex Pharmaceuticals Australia Pty Ltd)
Active ingredients
elexacaftor, tezacaftor and ivacaftor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Film-coated tablet
Indication
For the treatment of cystic fibrosis in patients who have at least one F508del mutation in the CFTR gene
Therapeutic area
Respiratory